This biotech company develops a non-viral gene integration platform for precision genome engineering. Their integrase-based technology enables the targeted insertion of large genes into the human genome, offering a safer and more efficient method for manufacturing biologics and vaccines.
Funding
Funding not disclosed
Founders
Product
Problem
Current genome engineering methods, such as CRISPR, face limitations in off-target editing, low efficiency, and the ability to insert large DNA fragments. Traditional methods can also rely on viral vectors or induce double-strand DNA breaks, potentially leading to unintended mutations and safety concerns.
Solution
Komo Biosciences offers a non-viral, integrase-based genome engineering platform for targeted insertion of large genes into the human genome. The platform utilizes highly evolved, hyperactive serine integrases to enable precise, site-specific integration with high efficiency. This technology overcomes the limitations of existing methods by enabling large gene insertion (7-15 kb) into a pre-defined, high-expressing region in the human genome at efficiencies of up to 80% per chromosome and 96% per cell, without inducing unprotected double-strand DNA breaks. The platform's scalability and predictability accelerate cell line development and manufacturing timelines for biologics and advanced therapies.
Target Audience
The primary customers are therapeutic developers and manufacturers of biologics, cell and gene therapies, and advanced therapies, as well as government entities focused on pandemic preparedness.
Features
- Proprietary KOMO FT™ cell lines driven by highly-evolved, hyperactive integrases
- Site-specific integration of large DNA fragments (7-15 kb)
- High integration efficiency (up to 80% per chromosome, 96% per cell)
- Non-viral delivery system
- Non-nuclease genome engineering, avoiding double-strand DNA breaks
- Rapid design-test cycles
- Antibiotic-free systems